

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED**

**阿里健康信息技術有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 00241)**

**COMPLETION OF THE PROPOSED ACQUISITION AND  
COMPLETION OF THE ISSUE OF CONSIDERATION SHARES  
UNDER THE SPECIFIC MANDATE**

References are made to the announcements dated November 28, 2023 and January 16, 2024 (the “**Announcements**”) and the circular dated December 22, 2023 (the “**Circular**”) of Alibaba Health Information Technology Limited (the “**Company**”) in relation to, among others, the Proposed Acquisition, the proposed allotment and issue of 2,558,222,222 Consideration Shares by the Company under the specific mandate and the poll results of the SGM convened to approve, among others, the Proposed Acquisition and the Share Purchase Agreement. Capitalised terms used herein shall have the same meanings as defined in the Announcements and the Circular unless the context requires otherwise.

**THE COMPLETION OF THE PROPOSED ACQUISITION**

The Board announces that all conditions precedent of the Proposed Acquisition under the Share Purchase Agreement have been fulfilled, and the Completion took place on January 17, 2024 in accordance with the terms and conditions of the Share Purchase Agreement. A total number of 2,558,222,222 Consideration Shares have been allotted and issued to the Vendor pursuant to the terms and conditions of the Share Purchase Agreement at the Issue Price of HK\$4.50 per Share, and the Target Company has become a wholly-owned subsidiary of the Company.

**FILING WITH THE REGULATORY AUTHORITIES IN THE PRC**

After the completion of the allotment and issue of the Consideration Shares, the Company will file with the regulatory authorities in the PRC in accordance with the relevant applicable laws and regulations, including the filing with the CSRC.

## EFFECTS ON SHAREHOLDING STRUCTURE OF THE COMPANY

The Consideration Shares represent approximately 18.90% of the issued share capital of the Company immediately before the Completion, and approximately 15.90% of the issued share capital of the Company as enlarged by the issue of the Consideration Shares. Set out below is the shareholding structure of the Company immediately before and after the Completion:

	Immediately before the Completion		Immediately after the Completion	
	<i>Number of Shares</i>	<i>%</i>	<i>Number of Shares</i>	<i>%</i>
— Perfect Advance Holding Limited	3,103,816,661	22.93	3,103,816,661	19.29
— Alibaba Investment Limited	48,716,465	0.36	48,716,465	0.30
— Ali JK Nutritional Products Holding Limited	4,560,785,407	33.70	4,560,785,407	28.34
— Antfin (Hong Kong) Holding Limited	60,576,000	0.45	60,576,000	0.38
— Uni-Tech International Group Limited	777,484,030	5.74	777,484,030	4.83
— Taobao Holding Limited	—	—	2,558,222,222	15.90
— Directors of the Company	3,201,442	0.02	3,201,442	0.02
— Other shareholders	<u>4,978,919,537</u>	<u>36.80</u>	<u>4,978,934,037</u>	<u>30.94</u>
Total	<u>13,533,499,542</u>	<u>100%</u>	<u>16,091,736,264</u>	<u>100%</u>

By Order of the Board  
**ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED**  
**ZHU Shunyan**  
*Chairman*

Hong Kong, January 17, 2024

*As at the date of this announcement, the Board comprises Mr. Zhu Shunyan, Mr. Shen Difan and Mr. Tu Yanwu as the executive Directors; Ms. Huang Jiaojiao and Mr. Xu Haipeng as the non-executive Directors; and Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong as the independent non-executive Directors.*